Hims & Hers (HIMS) stock surged over 11% pre-market after the FDA opened the door to testosterone therapy for low libido. The move signals a major new growth pillar for the telehealth firm. Analysts cite the massive $100 billion peptide market opportunity as a key catalyst, driving bullish sentiment even amidst broader market volatility and recent software sector selloffs.